Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Isometheptene→

Isometheptene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
503-01-5
Molecular formula
C9H19N
Molecular weight
141.25 g/mol
Drug class
Sympathomimetic aminevasoconstrictor used in historical antimigraine combinations
Mechanism of action
Acts as an indirectly and directly sympathomimetic amine, promoting adrenergic vasoconstriction through release of noradrenaline and stimulation of peripheral alpha-adrenergic signalling. The proposed antimigraine effect is related to cranial vasoconstriction; its clinical role is historical and product-specific.
Indications / reported uses
  • Historically used for acute migraine or tension-type headache in fixed-dose combinations with analgesic and sedative components in selected countries. Current availability and authorisation vary by jurisdiction.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/Isometheptene · https://www.ncbi.nlm.nih.gov/mesh/?term=Isometheptene · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Sympathomimetic amine; vasoconstrictor used in historical antimigraine combinations

Mechanism of action

Acts as an indirectly and directly sympathomimetic amine, promoting adrenergic vasoconstriction through release of noradrenaline and stimulation of peripheral alpha-adrenergic signalling. The proposed antimigraine effect is related to cranial vasoconstriction; its clinical role is historical and product-specific.

General use cases

  • Historically used for acute migraine or tension-type headache in fixed-dose combinations with analgesic and sedative components in selected countries. Current availability and authorisation vary by jurisdiction.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Isometheptene Environmental Risk Assessment (ERA) (the Isometheptene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.